title: Efficacy and tolerability of slow-release gallopamil in patients with stable exercise-inducible angina pectoris.
abstract: The anti-ischemic properties and tolerability of a slow-release formulation (SR) of gallopamil were investigated in 118 patients with exercise-inducible ST-segment depression and stable angina pectoris in this double-blind, randomized, placebo-controlled, multicenter study. After a placebo run-in period (A) of 2-7 days and a 7-day open therapy period (B) with gallopamil SR, the patients were randomized to a double-blind 7-day period (C) to receive placebo or gallopamil SR 100 mg twice a day. Each patient was submitted to gradual upright bicycle ergometry and electrocardiography (ECG) at rest on the last 2 days of each period at 6 and 12 h postadministration (p.a.) In period C, exercise time and exercise tolerance remained significantly prolonged at 6 and 12 h after gallopamil SR administration in comparison with the placebo values. Additionally the sum of ST-segment depression and maximal ST-segment depression were significantly reduced by gallopamil SR at 6 h p.a. as were the frequency of angina attacks and nitroglycerin consumption. Four patients were withdrawn from the study because of gallopamil-related adverse events, which, however, were not serious. Constipation was noted in 2.5% of the patients. These data suggest that gallopamil SR is effective in reducing exercise-inducible ST-segment depression and increasing exercise tolerance with no serious adverse effects in patients with stable angina pectoris.
authors.affiliation: Medical Hospital B, Heart Centre Wuppertal, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Kottkamp
authors.forename: H
authors.initials: H
authors.lastname: Gülker
authors.forename: K
authors.initials: K
authors.lastname: Emmerich
authors.forename: H P
authors.initials: HP
authors.lastname: Koch
authors.forename: C
authors.initials: C
authors.lastname: Minge
mesh_terms: D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy* / Q000503:physiopathology; D003692:Delayed-Action Preparations; D004562:Electrocardiography; D015444:Exercise; D005260:Female; D005711:Gallopamil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D003692:Delayed-Action Preparations; D005711:Gallopamil